Introduction
Ipamorelin and CJC-1295 No DAC are two of the most widely studied growth hormone secretagogues in peptide research. While both stimulate growth hormone (GH) release from the anterior pituitary, they do so through entirely different receptor systems and signaling pathways. Understanding their distinct mechanisms is essential for researchers studying the GH axis.
What is Ipamorelin?
Ipamorelin is a selective pentapeptide growth hormone-releasing peptide (GHRP) that acts through the ghrelin receptor (GHS-R1a). With a molecular weight of ~711.85 Da, it stimulates GH release via phospholipase C and intracellular calcium signaling. Its hallmark feature is exceptional selectivity — it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels.
What is CJC-1295 No DAC?
CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino acid GHRH analog that acts through the GHRH receptor on pituitary somatotrophs. With a molecular weight of ~3,367.9 Da, it stimulates GH release via the cAMP/PKA signaling pathway. Its ~30-minute half-life produces pulsatile GH release patterns that mimic physiological GHRH signaling.
Key Differences
| Feature | Ipamorelin | CJC-1295 No DAC |
|---|---|---|
| Classification | GHRP (Growth Hormone Releasing Peptide) | GHRH analog |
| Target Receptor | GHS-R1a (Ghrelin receptor) | GHRH receptor |
| Signaling Pathway | PLC/Ca²?/PKC | cAMP/PKA |
| Size | 5 amino acids (711 Da) | 29 amino acids (3,367 Da) |
| Cortisol Effect | Minimal | Minimal |
| GH Pulse Pattern | Acute pulse | Acute pulse (~30 min) |
Synergistic Combination Research
The most significant area of combined ipamorelin + CJC-1295 No DAC research involves their synergistic effect on GH release. Because they activate different intracellular signaling cascades (calcium vs. cAMP), simultaneous administration produces GH amplitudes significantly greater than either peptide alone. This synergy has been well-documented and forms the basis for many GH axis research protocols.
Research has shown that the combination can produce 2-3x greater GH release compared to either peptide in isolation, making the paired protocol a standard in GH secretagogue research.
Research Applications Compared
GH Axis Studies
Ipamorelin is preferred for studying ghrelin receptor-mediated GH release in isolation. CJC-1295 No DAC is preferred for studying GHRH-mediated GH release. The combination is used for maximal GH stimulation research.
Body Composition
Both peptides individually influence body composition through GH/IGF-1 axis stimulation. The combination protocol is most commonly used in body composition research due to superior GH elevation.
Bone Research
Ipamorelin has specific published data on bone density effects. CJC-1295’s bone effects are primarily mediated through GH/IGF-1 elevation. Both are relevant for skeletal research.
Which to Choose for Research?
Use ipamorelin alone when studying ghrelin receptor biology or when cortisol-free GH stimulation is required. Use CJC-1295 No DAC alone when studying GHRH receptor biology or GHRH signaling. Use the combination for maximal, synergistic GH release research. Most current GH axis research employs the combination protocol.
Conclusion
Ipamorelin and CJC-1295 No DAC represent complementary approaches to growth hormone secretagogue research. Their distinct receptor targets and signaling mechanisms provide researchers with precise tools for studying different aspects of GH regulation, while their well-characterized synergy offers a powerful combined approach for maximal GH axis stimulation.
All products are sold strictly for research purposes only. Not for human consumption.